ECSP24020235A - Anticuerpos de transportador de monocarboxilato humano 1 y usos de estos - Google Patents
Anticuerpos de transportador de monocarboxilato humano 1 y usos de estosInfo
- Publication number
- ECSP24020235A ECSP24020235A ECSENADI202420235A ECDI202420235A ECSP24020235A EC SP24020235 A ECSP24020235 A EC SP24020235A EC SENADI202420235 A ECSENADI202420235 A EC SENADI202420235A EC DI202420235 A ECDI202420235 A EC DI202420235A EC SP24020235 A ECSP24020235 A EC SP24020235A
- Authority
- EC
- Ecuador
- Prior art keywords
- antibodies
- human
- monocarboxylate transporter
- mct1
- human monocarboxylate
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Plant Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163261177P | 2021-09-14 | 2021-09-14 | |
| US202163272903P | 2021-10-28 | 2021-10-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP24020235A true ECSP24020235A (es) | 2024-06-28 |
Family
ID=83558178
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSENADI202420235A ECSP24020235A (es) | 2021-09-14 | 2024-03-14 | Anticuerpos de transportador de monocarboxilato humano 1 y usos de estos |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US11987624B2 (enExample) |
| EP (1) | EP4402172A1 (enExample) |
| JP (2) | JP7753348B2 (enExample) |
| KR (1) | KR20240053656A (enExample) |
| AU (1) | AU2022347031B2 (enExample) |
| CA (1) | CA3230072A1 (enExample) |
| CL (1) | CL2024000733A1 (enExample) |
| CO (1) | CO2024003042A2 (enExample) |
| CR (1) | CR20240133A (enExample) |
| DO (1) | DOP2024000049A (enExample) |
| EC (1) | ECSP24020235A (enExample) |
| IL (1) | IL311253A (enExample) |
| JO (1) | JOP20240054A1 (enExample) |
| MX (1) | MX2024003115A (enExample) |
| TW (1) | TWI842088B (enExample) |
| WO (1) | WO2023044325A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3087259A1 (en) | 2018-01-05 | 2019-07-11 | Immunext, Inc. | Anti-mct1 antibodies and uses thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040132813A1 (en) | 2001-05-30 | 2004-07-08 | Brooks George A. | Glycerol-lactate esters for use as an energy supplement during exercise and recovery |
| WO2012178173A1 (en) | 2011-06-24 | 2012-12-27 | Centrose, Llc | Extracellular targeted drug conjugates |
| GB201418626D0 (en) | 2014-10-20 | 2014-12-03 | Univ London Queen Mary | Method |
| CA3087259A1 (en) * | 2018-01-05 | 2019-07-11 | Immunext, Inc. | Anti-mct1 antibodies and uses thereof |
-
2022
- 2022-09-13 TW TW111134587A patent/TWI842088B/zh active
- 2022-09-14 KR KR1020247011816A patent/KR20240053656A/ko active Pending
- 2022-09-14 US US17/932,039 patent/US11987624B2/en active Active
- 2022-09-14 AU AU2022347031A patent/AU2022347031B2/en active Active
- 2022-09-14 IL IL311253A patent/IL311253A/en unknown
- 2022-09-14 WO PCT/US2022/076400 patent/WO2023044325A1/en not_active Ceased
- 2022-09-14 CA CA3230072A patent/CA3230072A1/en active Pending
- 2022-09-14 JP JP2023515671A patent/JP7753348B2/ja active Active
- 2022-09-14 CR CR20240133A patent/CR20240133A/es unknown
- 2022-09-14 MX MX2024003115A patent/MX2024003115A/es unknown
- 2022-09-14 EP EP22783672.3A patent/EP4402172A1/en active Pending
-
2024
- 2024-03-12 CL CL2024000733A patent/CL2024000733A1/es unknown
- 2024-03-12 DO DO2024000049A patent/DOP2024000049A/es unknown
- 2024-03-13 JO JOJO/P/2024/0054A patent/JOP20240054A1/ar unknown
- 2024-03-13 CO CONC2024/0003042A patent/CO2024003042A2/es unknown
- 2024-03-14 EC ECSENADI202420235A patent/ECSP24020235A/es unknown
-
2025
- 2025-10-01 JP JP2025165282A patent/JP2026004435A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TWI842088B (zh) | 2024-05-11 |
| KR20240053656A (ko) | 2024-04-24 |
| WO2023044325A1 (en) | 2023-03-23 |
| CR20240133A (es) | 2024-05-06 |
| MX2024003115A (es) | 2024-06-19 |
| CL2024000733A1 (es) | 2024-08-30 |
| IL311253A (en) | 2024-05-01 |
| JP7753348B2 (ja) | 2025-10-14 |
| AU2022347031B2 (en) | 2026-07-23 |
| TW202330602A (zh) | 2023-08-01 |
| CA3230072A1 (en) | 2023-03-23 |
| DOP2024000049A (es) | 2024-06-16 |
| JP2026004435A (ja) | 2026-01-14 |
| WO2023044325A9 (en) | 2024-04-25 |
| CO2024003042A2 (es) | 2024-03-18 |
| JOP20240054A1 (ar) | 2024-03-13 |
| JP2023542639A (ja) | 2023-10-11 |
| US20230111363A1 (en) | 2023-04-13 |
| AU2022347031A1 (en) | 2024-03-14 |
| US11987624B2 (en) | 2024-05-21 |
| EP4402172A1 (en) | 2024-07-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2021000909A1 (es) | Anticuerpos estabilizadores de trem2 | |
| CO2022000660A2 (es) | Composiciones de proteína anti-vegf y métodos para producir la misma | |
| EA202092202A1 (ru) | Конструкции антител к ror | |
| EA201890145A1 (ru) | Антитела к фактору xi и способы их применения | |
| CL2024001304A1 (es) | Anticuerpos anti-cd19 humano | |
| CO2023008643A2 (es) | Anticuerpos anti-hla-g y uso de estos | |
| CL2025002941A1 (es) | Anticuerpos anti-sirp-alfa. | |
| CL2022000230A1 (es) | Anticuerpos anti-ms4a4a y métodos de uso de los mismos | |
| CL2021000849A1 (es) | Anticuerpos que se unen a la proteína de envoltura del virus zika y usos de los mismos (divisional de la solicitud no. 201900999) | |
| MX2020007033A (es) | Anticuerpos anti-mct1 y usos de estos. | |
| CL2022002520A1 (es) | Anticuerpos anti-sea de muc1 | |
| UY37598A (es) | Anticuerpos miméticos de fgf21 y usos de los mismos | |
| DOP2024000049A (es) | Anticuerpos de transportador de monocarboxilato humano 1 y usos de estos | |
| MX2022006941A (es) | Epítopos de y anticuerpos contra trpv1. | |
| ECSP22004680A (es) | Anticuerpos anti-angpt2 | |
| CO2025003205A2 (es) | Anticuerpos anti-lair1 humano | |
| EA201992324A1 (ru) | Анти-trem2 антитела и способы их применения |